Darzalex, which treats multiple myeloma, has become the first Johnson & Johnson drug to ever top $3 billion in quarterly ...
The plaintiff filed a motion for a new trial, arguing that, “At a minimum, the verdict shows confusion and lack of ...
An OB/GYN was terse in her feedback, saying she needed an answer to inquiries from patients on whether their ovarian cancer ...
J&J’s 2025 results will be the launching point for its guidance of 5%-7% revenue growth for 2025-30, which is still well ...
Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, ...
Johnson & Johnson ( JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to ...
The well-known actor Daniel Craig does not intend to leave his fortune to his children. He believes leaving a large ...
The New Jersey-based drugmaker expects 2025 sales of between $90.9 billion and $91.7 billion, and to earn between $10.75 and ...
Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.
Netflix beats forecasts, airline resurgence, AI ramp-up, and more ...
In a report released today, Anil Shenoy from Barclays maintained a Buy rating on Elementis (ELM – Research Report), with a price target of ...